ARTICLE | Company News
EC approves Opdivo-Yervoy combo for melanoma
May 12, 2016 1:23 AM UTC
Bristol-Myers Squibb Co. (NYSE:BMY) said the European Commission approved Opdivo nivolumab in combination with Yervoy ipilimumab to treat advanced melanoma in adults independent of BRAF mutation status. The company said it is the first combination of two immuno-oncology therapies to be approved in the EU. ...